Orotic Acid (Vitamin B13): The Former Vitamin and Mineral Carrier

Orotic acid is a genuine and important molecule — an intermediate your own body makes on the path to building the DNA and RNA letters called pyrimidines — but it is not a vitamin. It was briefly marketed as “vitamin B13” in the mid-twentieth century, yet because human cells synthesize it themselves, there is no orotic acid deficiency disease, no recommended daily allowance, and no Daily Value. Today it survives in two very different worlds: as a clinically meaningful clue in rare metabolic disease, and as a controversial “carrier” bonded to minerals in supplements such as magnesium orotate and lithium orotate.

What Is Orotic Acid
The “Vitamin B13” Story
Role in Pyrimidine (UMP) Synthesis
Hereditary Orotic Aciduria
A Urea-Cycle Diagnostic Clue
Mineral Orotates and the Nieper Claims
Lithium Orotate — A Caution
Magnesium Orotate and the Heart
Food Sources
Safety and the Fatty-Liver Model
Bottom Line
References
Connections
Featured Videos

1. What Is Orotic Acid

Orotic acid is a small organic molecule (chemically, a pyrimidinecarboxylic acid, formula C5H4N2O4) that occupies a fixed position in one of the most fundamental assembly lines in biology: the de novo synthesis of pyrimidine nucleotides. Pyrimidines are one of the two families of nitrogen-containing “letters” that, together with purines, spell out DNA and RNA. Without a steady supply of pyrimidines, no cell can copy its genome or build the messenger RNA needed to make proteins, so every dividing cell in the body depends on this pathway.

The crucial point for anyone evaluating supplement marketing is this: the human body manufactures orotic acid itself. It is an internal intermediate, not a dietary requirement. You do not need to eat orotic acid to be healthy, you cannot develop an orotic acid deficiency disease, and — unlike true vitamins such as vitamin C or folate — there is no established human requirement, no RDA, and no FDA Daily Value for it. Any product claiming a “recommended intake” of vitamin B13 is describing a nutrient category that the scientific community abandoned decades ago.

Orotic acid was first described in cow's milk in the nineteenth century — its name derives from the Greek oros, meaning whey — and for that reason dairy and whey remain its most cited dietary sources. But the orotic acid circulating in your blood and tissues comes overwhelmingly from your own cells, particularly the liver, as a normal by-product of pyrimidine manufacturing.

2. The “Vitamin B13” Story

The label “vitamin B13” is a historical artifact from an era when the B-complex was being rapidly expanded and many growth-promoting factors were provisionally numbered before their biochemistry was understood. Mid-twentieth-century researchers observed that orotic acid could support the growth of certain microorganisms and laboratory animals under specific conditions, and in that spirit it was tentatively classified as a member of the B-vitamin family. Several other compounds received the same speculative treatment around the same time — PABA was called “B10,” pangamic acid “B15,” and the cyanide-containing extract laetrile “B17” — and like orotic acid, none of them survived scientific scrutiny as genuine vitamins.

The reclassification was decisive and is not controversial among biochemists. A true vitamin is, by definition, an organic compound that the body cannot synthesize in adequate amounts and must therefore obtain from the diet to prevent a specific deficiency disease. Orotic acid fails this test on every count: the body makes it, no deficiency syndrome exists when it is absent from the diet, and removing it from food has no measurable consequence for health. Foundational work on human pyrimidine metabolism in the late 1950s made clear that orotic acid is an endogenous metabolic intermediate rather than an essential dietary factor, and the “B13” designation was quietly retired.

It is worth being plain about this on a health-information site: “vitamin B13” is a deprecated, non-official term. The molecule is real and biologically important; the vitamin status is not. The term persists almost entirely in supplement marketing, where the lingering aura of a “B vitamin” lends unearned credibility to orotate products.

3. Role in Pyrimidine (UMP) Synthesis

To understand orotic acid honestly, it helps to see exactly where it sits in the pathway. The de novo pyrimidine biosynthesis pathway builds the pyrimidine ring from simple precursors — glutamine, bicarbonate, and aspartate — through a series of enzyme-catalyzed steps. The pathway converges on orotic acid (orotate), which is then converted, in two final steps, into uridine monophosphate (UMP), the parent compound from which all other pyrimidine nucleotides (UTP, CTP, and the DNA building blocks dTMP and dCMP) are ultimately derived.

Those last two steps are the biochemically famous part. Orotate is first joined to a ribose-phosphate sugar to form orotidine monophosphate (OMP), and OMP is then decarboxylated to yield UMP. In humans both reactions are carried out by a single bifunctional enzyme, UMP synthase (UMPS), which carries two enzyme activities — orotate phosphoribosyltransferase and OMP decarboxylase — fused into one protein. The regulation of this pathway, and the genes and enzymes that drive it, were mapped out in detail by classic biochemical work in the late twentieth century.

The sequence is worth committing to memory because it explains everything else on this page: aspartate → (several steps) → orotate → OMP → UMP. When this final stretch works normally, orotic acid is a fleeting intermediate that never accumulates. When the last enzyme fails, orotic acid backs up like water behind a dam — and that backup is the basis of both the rare disease and the diagnostic test described in the next two sections.

4. Hereditary Orotic Aciduria

Hereditary orotic aciduria is a rare inherited disorder caused by a deficiency of the UMP synthase enzyme — the very enzyme that converts orotate into UMP. It is inherited in an autosomal recessive pattern, meaning a child must inherit a non-working copy of the UMPS gene from each parent to be affected. Because the cell can no longer complete the conversion of orotate to UMP, two things happen at once: the body runs short of pyrimidine nucleotides needed for cell division, and unused orotic acid spills over into the blood and is excreted in large amounts in the urine (hence the name).

The clinical hallmark is a megaloblastic anemia — large, immature red blood cells — that begins in infancy and, crucially, does not respond to vitamin B12 or folate, the two deficiencies that usually cause megaloblastic anemia. This is a vital diagnostic distinction: a megaloblastic anemia that ignores B12 and folate supplementation, especially in a child also showing failure to thrive and developmental delay, should prompt clinicians to consider a pyrimidine-synthesis defect. Affected children may also pass orotic acid crystals in the urine.

The elegant part of the story is the treatment. Because the block is specifically at the orotate-to-UMP step, the disorder can be bypassed by supplying the downstream product directly: oral uridine (or uridine triacetate) restores the pyrimidine supply the body cannot make for itself, correcting the anemia and supporting normal growth. The first cases were described and characterized in the 1950s and 1960s — a landmark 1965 report documented a patient whose anemia responded to uridine — and later genetic work, including the identification of specific UMPS mutations, confirmed the molecular basis. The condition remains exceptionally rare, with only a small number of families described worldwide, but it is the clearest illustration of why orotic acid matters biologically.

5. A Urea-Cycle Diagnostic Clue

Orotic acid earns its place in clinical medicine for a second, entirely separate reason: it is a valuable diagnostic marker in the urea cycle disorders. The urea cycle is the liver's system for converting toxic ammonia (a by-product of protein breakdown) into harmless urea for excretion. When one of the cycle's enzymes is defective, ammonia builds up in the blood — a dangerous condition called hyperammonemia — and intermediates of the cycle are diverted into other pathways.

One of those diversions feeds directly into pyrimidine synthesis. In ornithine transcarbamylase (OTC) deficiency, the most common urea cycle disorder, the substrate carbamoyl phosphate accumulates upstream of the blocked enzyme and is shunted into the pyrimidine pathway, where it is ultimately converted into — and excreted as — orotic acid. The result is that a child or adult presenting with unexplained high blood ammonia, together with elevated urinary orotic acid, points strongly toward OTC deficiency or related defects, whereas hyperammonemia without elevated orotic acid points toward a different point of failure in the cycle (such as carbamoyl phosphate synthetase deficiency).

This branch-point logic, worked out in the metabolic literature of the early 1980s, is why urinary orotic acid is a standard part of the diagnostic workup for hyperammonemia. Here, orotic acid is not something anyone takes — it is a fingerprint the body leaves behind that helps physicians pinpoint exactly which enzyme has failed, guiding urgent, life-saving treatment.

6. Mineral Orotates and the Nieper Claims

The supplement world's interest in orotic acid has almost nothing to do with the biochemistry above. Instead, it centers on mineral orotates — salts in which a mineral (magnesium, calcium, zinc, lithium, potassium) is paired with orotate as its counter-ion. These were popularized in the 1970s and 1980s by the German physician Hans Nieper, who proposed an “electrolyte carrier” or “mineral transporter” theory: he argued that bonding a mineral to orotic acid produced an electrically neutral, lipophilic complex that could ferry the mineral intact across cell membranes and deliver it directly inside the cell, making orotate salts dramatically more bioavailable and “cell-permeable” than ordinary mineral salts.

An honest reading of the evidence requires real skepticism here. Nieper's carrier theory is not well supported by rigorous, independent, modern pharmacokinetic research. The claim that an intact magnesium-orotate molecule survives digestion and is absorbed and delivered into cells as a unit runs against the basic chemistry of how ionic salts dissociate in the gut. In practice, most evidence suggests orotate salts dissolve into their separate mineral and orotate components, after which the mineral is absorbed by the same transporters that handle any other mineral source. Head-to-head data showing orotate forms to be meaningfully superior to well-studied alternatives — magnesium glycinate or citrate, for example — are sparse and not convincing.

This does not make mineral orotates worthless. They do deliver their mineral, and they are generally well tolerated. But the specific marketing promise — that orotate is a uniquely powerful intracellular delivery vehicle — rests largely on Nieper's own theory and writings rather than on the kind of replicated, controlled human absorption studies that would justify the premium often charged for these products. Consumers are usually better served by choosing a mineral form on the basis of established tolerability and cost than on the orotate “carrier” claim.

7. Lithium Orotate — A Caution

Lithium orotate deserves its own section because it is widely sold over the counter as a “natural,” low-dose form of lithium — often marketed for mood, stress, and brain health — and because the marketing can give a dangerously misleading impression of safety. The pitch typically claims that the orotate carrier delivers lithium so efficiently into cells that tiny doses (commonly 5 mg of elemental lithium per tablet) rival the effects of prescription lithium carbonate, which is dosed at hundreds of milligrams under careful medical supervision.

The reality is that the efficacy and safety of lithium orotate are not established to anything like the standard that governs prescription lithium. Prescription lithium (as carbonate or citrate) is one of the most rigorously studied and closely monitored drugs in psychiatry, with a famously narrow therapeutic window: too little does nothing, too much causes serious toxicity affecting the kidneys, thyroid, and nervous system, and patients require regular blood-level monitoring. The notion that lithium orotate sidesteps these concerns rests on the same unproven Nieper carrier theory discussed above. An older animal study comparing lithium orotate and lithium carbonate raised questions about how lithium from the orotate form distributes and is handled by the kidney, and a more recent critical review concluded that the case for lithium orotate as a “superior” lithium therapy is not supported by adequate human evidence.

The practical bottom line is caution. Self-treating a mood disorder with over-the-counter lithium orotate is not a substitute for proper psychiatric care, the actual delivered dose and tissue exposure are not well characterized, and combining it with other medications or with prescription lithium could be hazardous. Anyone considering lithium for a genuine medical reason should do so only under a physician's supervision. For the prescription mineral salt and its established clinical use, see our page on Lithium Carbonate.

8. Magnesium Orotate and the Heart

Of all the mineral orotates, magnesium orotate has the most actual clinical research behind it, primarily in cardiology — though the evidence should be presented cautiously rather than oversold. Magnesium itself is genuinely important for heart rhythm and vascular function, so the relevant question is whether the orotate form, specifically, offers something extra.

A small number of trials have explored this. In patients with stable coronary heart disease, a 1998 study reported that magnesium orotate improved exercise tolerance compared with placebo. More notably, the MACH study (Magnesium in Congestive Heart Failure), published in 2009, examined magnesium orotate as add-on therapy in patients with severe congestive heart failure and reported improved survival and clinical symptoms over roughly a year of treatment compared with placebo. These are real, peer-reviewed results and they are the strongest data any mineral orotate can point to.

The appropriate response, however, is measured interest rather than enthusiasm. These trials are small, relatively few in number, and not of the large, multi-center, high-quality design that would establish magnesium orotate as a standard treatment. They have not been widely replicated, and crucially, none of them demonstrate that the orotate component is responsible for any benefit — the magnesium itself is the obvious active ingredient, and a comparison against other magnesium salts would be needed to credit the carrier. Magnesium orotate is not part of mainstream heart-failure guidelines. It is reasonable to describe these findings honestly as promising but preliminary and low-certainty, and to note that anyone with heart failure or coronary disease should make supplement decisions with their cardiologist, not on the basis of supplement labels.

9. Food Sources

Because orotic acid is not an essential nutrient, “food sources” are a matter of curiosity rather than dietary planning — you do not need to seek it out. Still, it does occur naturally in food, and its history is bound up with one food in particular: milk and other dairy products. Orotic acid was originally isolated from cow's milk whey, and ruminant milk (cow, goat, sheep) remains the richest and most frequently cited dietary source. Whey — the liquid fraction left after milk is curdled — concentrates much of the orotic acid, which is why whey and whey-protein products are associated with it.

Smaller amounts are present in certain root vegetables and other plant foods, but the quantities are modest and inconsistent across sources. No food provides orotic acid in amounts remotely comparable to a supplement dose, and there is no nutritional reason to try to maximize dietary intake. For the overwhelming majority of people, the orotic acid that matters physiologically is the amount their own cells produce internally as part of normal pyrimidine metabolism — not the trace amounts in a glass of milk.

10. Safety and the Fatty-Liver Model

At the trace levels found in food, orotic acid raises no safety concerns whatsoever — people have consumed it in dairy for as long as they have drunk milk. The relevant safety discussion concerns higher, supplemental intakes, and here there is one classic finding worth knowing about.

In experimental science, feeding rats a diet enriched with orotic acid is a well-established laboratory method for inducing fatty liver (hepatic steatosis). For decades, dietary orotic acid has been used precisely because it reliably produces fat accumulation in the rodent liver, making it a convenient experimental model for studying how fatty liver develops and how it might be prevented. A 1963 study even documented a sex difference in how readily orotic acid induced fatty liver in rats. The proposed mechanisms involve interference with the liver's packaging and export of fats (very-low-density lipoprotein secretion) and disturbances in nucleotide balance within liver cells.

The honest interpretation is one of uncertainty rather than alarm. The rat fatty-liver effect is robust, but it is produced by feeding orotic acid as a substantial fraction of the diet — doses far larger, relative to body weight, than the small amounts present in mineral-orotate supplements. Rodents and humans also differ in how they metabolize orotate. Whether ordinary human supplement doses pose any liver risk is not well established, and there is no good evidence of fatty liver from mineral orotates at typical use. Nonetheless, the existence of this model is a legitimate reason to avoid high-dose orotic acid supplementation, to be skeptical of products that pile on large amounts of orotate as a “carrier,” and to favor mineral forms whose safety is better characterized.

11. Bottom Line

Orotic acid is a real and elegant piece of human biochemistry wearing a misleading marketing name. As an internal intermediate on the road from aspartate to UMP, it is essential to the life of every dividing cell — but it is not a vitamin, there is no deficiency disease, and the term “vitamin B13” is a deprecated historical label that should not be taken to imply a dietary requirement. Where it genuinely matters in medicine is at the bedside: as the molecule that backs up in hereditary orotic aciduria (a rare anemia treated with uridine, not iron or B12), and as a urinary clue that helps physicians diagnose urea-cycle disorders such as OTC deficiency.

As a supplement, the picture calls for measured skepticism. The mineral-orotate “carrier” theory popularized by Hans Nieper is not well supported by rigorous modern evidence; magnesium orotate has a handful of small, low-certainty cardiology trials that are interesting but far from definitive; and lithium orotate, despite its “natural” image, has no established safety or efficacy profile and should never be treated as a casual over-the-counter substitute for properly supervised lithium therapy. A classic rodent model linking high-dose orotic acid to fatty liver is a further reason not to consume large amounts. For most people, the practical takeaway is simple: there is no need to seek orotic acid out, and when choosing a mineral supplement, base the decision on well-studied tolerability and cost rather than on the orotate “vitamin B13” mystique.

References

Smith, L.H., and Baker, F.A. "Pyrimidine Metabolism in Man. I. The Biosynthesis of Orotic Acid." Journal of Clinical Investigation, vol. 38, no. 5, 1959, pp. 798-809.
Jones, M.E. "Pyrimidine Nucleotide Biosynthesis in Animals: Genes, Enzymes, and Regulation of UMP Biosynthesis." Annual Review of Biochemistry, vol. 49, 1980, pp. 253-279.
Becroft, D.M.O., and Phillips, L.I. "Hereditary Orotic Aciduria and Megaloblastic Anaemia: A Second Case, with Response to Uridine." British Medical Journal, vol. 1, no. 5434, 1965, pp. 547-552.
Bailey, C.J. "Orotic Aciduria and Uridine Monophosphate Synthase: A Reappraisal." Journal of Inherited Metabolic Disease, vol. 32, suppl. 1, 2009, pp. 227-233.
Al Absi, H.S., Sacharow, S., Al Zein, N., et al. "Hereditary Orotic Aciduria (HOA): A Novel Uridine-5-Monophosphate Synthase (UMPS) Mutation." Molecular Genetics and Metabolism Reports, vol. 26, 2021, article 100703.
Bachmann, C., and Colombo, J.P. "Orotic Acid in Urine and Hyperammonemia." Advances in Experimental Medicine and Biology, vol. 153, 1982, pp. 313-319.
Stepura, O.B., and Martynow, A.I. "Magnesium Orotate in Severe Congestive Heart Failure (MACH)." International Journal of Cardiology, vol. 131, no. 2, 2009, pp. 293-295.
Geiss, K.R., Stergiou, N., Jester, I., Neuenfeld, H.U., and Jester, H.G. "Effects of Magnesium Orotate on Exercise Tolerance in Patients with Coronary Heart Disease." Cardiovascular Drugs and Therapy, vol. 12, suppl. 2, 1998, pp. 153-156.
Pacholko, A.G., and Bekar, L.K. "Lithium Orotate: A Superior Option for Lithium Therapy?" Brain and Behavior, vol. 11, no. 8, 2021, e2262.
Smith, D.F., and Schou, M. "Kidney Function and Lithium Concentrations of Rats Given an Injection of Lithium Orotate or Lithium Carbonate." Journal of Pharmacy and Pharmacology, vol. 31, no. 1, 1979, pp. 161-163.
Sidransky, H., and Clark, S. "Sex Difference in Induction of Fatty Liver in the Rat by Dietary Orotic Acid." Endocrinology, vol. 72, no. 5, 1963, pp. 709-714.

↑ Back to Table of Contents

Connections